Listen
Reason for request
Key points
Favourable opinion for maintenance of reimbursement as monotherapy for the treatment of adult patients with BRAF mutation-positive unresectable or metastatic melanoma.
What therapeutic improvement ?
No clinical added value in the therapeutic strategy.
Role in the care pathway ?
In the presence of BRAF V600 mutation in metastatic melanoma, the strategy is based on targeted dual therapy including the combination of a BRAF inhibitor and a MEK inhibitor: dabrafenib + trametinib, vemurafenib + cobimetinib or encorafenib + binimetinib. The latter combination has demonstrated an increase in progression-free survival compared to vemurafenib but has not demonstrated an increase in overall survival compared to vemurafenib or dabrafenib as monotherapy, in contrast with other BRAF/MEK inhibitors.
The role of nivolumab and pembrolizumab as an alternative to these targeted therapies is currently the subject of debate, as is the profile of patients suitable for receiving either of these two therapies as a first-line treatment.
The use of a BRAF inhibitor as monotherapy in BRAF V600 mutation-positive patients is only recommended in the event of contraindication or intolerance to MEK inhibitors.
Role of the medicinal product in the care pathway
ZELBORAF as monotherapy now has a limited role as first-line therapy only in the event of contraindication or intolerance to MEK inhibitors.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of ZELBORAF (vemurafenib) as monotherapy remains substantial in the MA indication.
|
Clinical Added Value
| no clinical added value |
Considering :
the Committee considers that ZELBORAF as monotherapy provides no clinical added value (CAV V) in the care pathway for BRAF V600 mutation-positive unresectable or metastatic melanoma.
|
